Regulatory milestones

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed under a $160 million contract with HHS's Biomedical Advanced Research and Development Authority (BARDA).